Kristina Goutsouliak, MD
Medical Oncology · Grand Junction, CONPI 1447690938
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $937 of the $1,441 with a category attached, or 65.0%. 15 manufacturers reported payments, led by Seagen Inc. at 31.1% of the total. That places this record below the midpoint for medical oncology clinicians in CO, where the typical reported total is $1,342.
Across 43 payments — averaging $33.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$448
- Pfizer$229
- AstraZeneca$223
- Bristol Myers Squibb$137
- E.r. Squibb & Sons, L.L.C.$101
- AbbVie$80
- plus $223 from 9 others
Across 3 payments — averaging $3379.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
- Merck$138
What the payments were for
- Food & beverage$93765%
- Education$50435%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 6 | $448 |
| Pfizer | 9 | $229 |
| AstraZeneca | 6 | $223 |
| Bristol Myers Squibb | 2 | $137 |
| E.r. Squibb & Sons, L.L.C. | 5 | $101 |
| AbbVie | 3 | $80 |
| Sirtex Medical Inc | 1 | $39 |
| Novartis | 2 | $39 |
| Amgen | 2 | $37 |
| Rigel Pharmaceuticals, Inc. | 2 | $32 |
| Bayer | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$108
How this compares
$1,441 in reported general payments places this provider in the 50th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 26 | $38,643 |
| EliquisApixaban | 12 | $11,954 |
| Exemestane | 52 | $4,459 |
| Enoxaparin Sodium | 14 | $3,885 |
| Letrozole | 171 | $3,177 |
| Dexamethasone | 68 | $1,338 |
| Hydroxyurea | 32 | $1,308 |
| Ondansetron Hcl | 111 | $853 |
| Prochlorperazine Maleate | 99 | $851 |
| Acyclovir | 30 | $820 |
| Tamoxifen Citrate | 29 | $693 |
| Olanzapine | 42 | $610 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 49 | $587 |
| Oxycodone Hcl | 25 | $459 |
| Potassium Chloride | 33 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $229 | $11,95412 claims |
| Lilly USA, LLCOlanzapine | $16 | $61042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 96 medical oncology providers in Colorado.
Other medical oncology in Grand Junction
- Jonathan KingGrand Junction$4K
- Allan MillerGrand Junction$1K
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Chelsea GawryletzFort Collins$301K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.